Apogee Therapeutics (NASDAQ:APGE) Trading Up 5.2%

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) rose 5.2% during trading on Tuesday . The company traded as high as $49.96 and last traded at $49.96. Approximately 46,632 shares were traded during trading, a decline of 91% from the average daily volume of 514,914 shares. The stock had previously closed at $47.51.

Analyst Ratings Changes

Separately, Wedbush reissued an "outperform" rating and issued a $87.00 target price on shares of Apogee Therapeutics in a research report on Monday, May 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $78.50.

Apogee Therapeutics Stock Up 4.2 %

The company has a 50 day simple moving average of $45.98 and a 200 day simple moving average of $49.27. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -9.52 and a beta of 2.75.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.60). On average, research analysts forecast that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the transaction, the chief executive officer now owns 1,434,487 shares in the company, valued at approximately $58,268,861.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Apogee Therapeutics news, insider Carl Dambkowski sold 7,335 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $40.67, for a total value of $298,314.45. Following the completion of the sale, the insider now owns 287,458 shares of the company's stock, valued at $11,690,916.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the business's stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the transaction, the chief executive officer now directly owns 1,434,487 shares in the company, valued at $58,268,861.94. The disclosure for this sale can be found here. Insiders sold 120,995 shares of company stock valued at $5,218,774 over the last 90 days. Corporate insiders own 36.10% of the company's stock.

Hedge Funds Weigh In On Apogee Therapeutics

A number of institutional investors have recently added to or reduced their stakes in APGE. Arizona State Retirement System increased its position in shares of Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock worth $236,000 after acquiring an additional 258 shares during the last quarter. EntryPoint Capital LLC boosted its stake in shares of Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after buying an additional 617 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Apogee Therapeutics by 26.3% during the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock worth $253,000 after buying an additional 1,340 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Apogee Therapeutics by 28.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,155 shares of the company's stock worth $475,000 after buying an additional 1,600 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Apogee Therapeutics by 111.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock valued at $274,000 after acquiring an additional 2,172 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.